Another inconvenient truth out of Senate Estimates when I asked Professor Skerritt why the TGA hadn’t attached a warning label to the C-19 vaccine boxes for people with autoimmune antiphospholipid syndrome (APS).
The studies he cherry picked, including the Rheumatology journal article, had no relevance to Natalie’s case. That article was the Sinopharm vaccine from China, not available in Australia and contained no phospholipids.
Natalie had two Pfizer jabs and a Moderna booster in February 2022. To our knowledge there have been zero studies on boosters for those with APS, let alone mixing the jabs.
The TGA would have known Sweden, Denmark and Finland pulled the Moderna vaccine for anyone under 30 in October 2021.
How can Skerritt downplay concerns about a warning label when it could have prevented Natalie’s death?
Following the science means not having blinders up. There was and is no evidence to prove that a triple-jabbed young lady like Natalie with APS would be safely jabbed and boosted. That is why she died.
The TGA failed her.
In spite of many anecdotal reports on the development of thrombotic events in recipients of COVID-19 vaccines, scientific evidence relying on published cases on peer-reviewed journals is limited. Nevertheless, lessons from pre−COVID-19 vaccines taught that vaccine-related injuries may be identified several years following the date of the vaccine campaign introduction and after a large number of individuals have been vaccinated . In addition, side effects occurring in a minority of people belonging to specific populations (like aPL-positive subjects) may be underestimated.
Sinopharm study in Rheumatology –
Community Affairs Legislation Committee
HEALTH AND AGED CARE PORTFOLIO
Australian Health Practitioner Regulation Agency
Senator RENNICK: I will dispute that, but that’s not what I’ll dispute right now. There’s a 21-year-old female who died from the Moderna vaccine. She had an antiphospholipid syndrome, which is an autoimmune disease. The vaccine was never tested on people with autoimmune diseases. Why haven’t you put a label on the actual vaccine to warn people if they have an antiphospholipid syndrome, which is one in 2,000 people, higher than the rate of multi-inflammatory disease that you have said is one in 3,000. Why haven’t you put a label on the vaccine to warn people about that?
Dr Skerritt : Again, I’ve got to pick you up on your science. First of all, antiphospholipid syndrome is actually even a bit more common than that. It might be one per cent of people. So it’s a considerably common condition. Because it was a common condition, early in the rollout of the vaccines it was indeed studied whether people with antiphospholipid syndrome had an increased risk after vaccination. There were international studies carried out published in the world’s top medical journals. There was a study using Italian patients. There was a study using Turkish patients. I believe the third study was done in British patients. Let me just quote from one of them:
The COVID vaccine does not increase the risk of thrombolitic events among patients with antiphospholipid syndrome, according to study results published in Rheumatology.
Rheumatology is a top journal which would cover people with antiphospholipid syndrome. I will then go to the patient group. There’s actually a patient support group in the UK for people who have antiphospholipid syndrome. I will read from their web advice to patients:
There is no evidence to suggest that patients with antiphospholipid syndrome were at increased risk of complications from the available COVID vaccines.